Max Planck Innovation GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Max Planck Innovation GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH141610D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Max Planck Innovation GmbH (Max Planck), formerly Garching Innovation GmbH, a subsidiary of Max Planck Society is a technology transfer company that offers transferring inventions and technologies. The company offers advisory and support services to scientists in evaluating inventions, filing patent applications, advance their technology, negotiate and close license agreements, and founding companies. It provides industry with access to the inventions of various Max Planck Institutes. Max Planck serves various industries in the areas of diagnostics, therapeutics, plant biotechnology, biotechnology methods and processes, analytics, new materials, devices, sensors and components and software. The company works with scientific community and industry including professional investors, lawyers, patent attorneys and tax consultants, scientific experts and company representatives. Max Planck is headquartered in Munich, Germany.

Max Planck Innovation GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Max Planck Innovation GmbH, Medical Devices Deals, 2011 to YTD 2017 10

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

UGISense to Raise USD1.3 Million Venture Financing 14

Partnerships 15

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 15

Arix Bioscience, Lead Discovery Center, Max Planck Innovation and University of Leeds Enter into Partnership 16

Lead Discovery Center to Enter into Development Agreement with UGISense 17

Lead Discovery Center Enters into Research Agreement with McGill University 18

LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 19

Lead Discovery Center to Enter into Drug Discovery Agreement with Roche 20

Lead Discovery Center Partners with Infinity Pharma 21

Wave Life Sciences Enters into Licensing Agreement with Max Planck Innovation 22

Johnson & Johnson Innovation Partners with Lead Discovery Center 24

AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 25

Lead Discovery Center Enters into Research Agreement with Helmholtz Center 26

Qurient Enters into Agreement with Lead Discovery Center 27

Lead Discovery Center Enters into Agreement with UiT The Arctic University of Norway 28

Lead Discovery Center Partners with Helmholtz Association of German Research Centres 29

Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 30

Lead Discovery Center, Centre for Drug Design and Discovery and Axxam Form Joint Venture 31

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 32

AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 33

CDRD Enters Into An Agreement With Lead Discovery Center 34

Lead Discovery Center Enters Into Agreement With Merck Serono 35

Licensing Agreements 36

Sotio Enters into Licensing Agreement with Lead Discovery Center 36

Vaxxilon Enters into Licensing Agreement with Max-Planck Innovation 37

Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 38

Lead Discovery Center Enters into Licensing Agreement with Qurient 39

Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 40

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 42

Lead Discovery Enters Into Licensing Agreement With Bayer Schering 43

Max Planck Innovation GmbH-Key Competitors 44

Max Planck Innovation GmbH-Key Employees 45

Max Planck Innovation GmbH-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Max Planck Innovation GmbH, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Max Planck Innovation GmbH, Deals By Therapy Area, 2011 to YTD 2017 9

Max Planck Innovation GmbH, Medical Devices Deals, 2011 to YTD 2017 10

Max Planck Innovation GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

UGISense to Raise USD1.3 Million Venture Financing 14

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 15

Arix Bioscience, Lead Discovery Center, Max Planck Innovation and University of Leeds Enter into Partnership 16

Lead Discovery Center to Enter into Development Agreement with UGISense 17

Lead Discovery Center Enters into Research Agreement with McGill University 18

LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 19

Lead Discovery Center to Enter into Drug Discovery Agreement with Roche 20

Lead Discovery Center Partners with Infinity Pharma 21

Wave Life Sciences Enters into Licensing Agreement with Max Planck Innovation 22

Johnson & Johnson Innovation Partners with Lead Discovery Center 24

AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 25

Lead Discovery Center Enters into Research Agreement with Helmholtz Center 26

Qurient Enters into Agreement with Lead Discovery Center 27

Lead Discovery Center Enters into Agreement with UiT The Arctic University of Norway 28

Lead Discovery Center Partners with Helmholtz Association of German Research Centres 29

Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 30

Lead Discovery Center, Centre for Drug Design and Discovery and Axxam Form Joint Venture 31

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 32

AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 33

CDRD Enters Into An Agreement With Lead Discovery Center 34

Lead Discovery Center Enters Into Agreement With Merck Serono 35

Sotio Enters into Licensing Agreement with Lead Discovery Center 36

Vaxxilon Enters into Licensing Agreement with Max-Planck Innovation 37

Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 38

Lead Discovery Center Enters into Licensing Agreement with Qurient 39

Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 40

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 42

Lead Discovery Enters Into Licensing Agreement With Bayer Schering 43

Max Planck Innovation GmbH, Key Competitors 44

Max Planck Innovation GmbH, Key Employees 45

Max Planck Innovation GmbH, Subsidiaries 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Max Planck Innovation GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com